

DEPARTMENT OF HEALTH

NO. 2342

5 August 2022

**MEDICINES AND RELATED SUBSTANCES ACT, (ACT NO. 101 OF 1965)
(ANNUAL SINGLE EXIT PRICE ADJUSTMENT (SEPA) OF MEDICINES AND SCHEDULED
SUBSTANCES FOR THE YEAR 2023)**

In terms of Regulation 8 (1) of the Regulations Relating to the Transparent Pricing System for Medicines and Scheduled Substances of the Medicines and Related Substances Act, 1965 (No. 101 of 1965) as amended, the Minister of Health is required to determine on an annual basis, the extent to which medicine prices may be adjusted. In making this determination the Minister considers the following provisions of

Regulation 8 (1)-

- (a) the average CPI for the preceding year;
- (b) the average PPI for the preceding year;
- (c) changes in the rates of foreign exchange and purchasing power parity;
- (d) international pricing information relating to medicines and scheduled substances;
- (e) comments received from interested persons in terms of regulation 8(2); and
- (f) the need to ensure the availability, affordability and quality of medicines and scheduled substances in the Republic.

Based on the comments received from previous annual reviews on the adjustment methodology, stakeholders have recommended a CPI weighting and a foreign exchange weighting in the review of the annual SEP adjustment expressed as follows:

- (a) 70% (South African CPI) + 30% (foreign exchange rate) = % adjustment Or
- (b) 50% (South African CPI) + 50% (foreign exchange rate) = % adjustment Or
- (c) 100% Foreign exchange rate = % adjustment Or
- (d) 100% South African CPI = % adjustment.

The Pricing Committee in its recommendation for the next annual adjustment cycle may consider the weighting(s) *in addition* to the provisions of Regulation 8(1) as listed above.

The official data to be used with respect to the Consumer Price Index (CPI) for South Africa and the foreign exchange rates would be obtained from official publications by the Statistics South Africa at www.statssa.gov.za and the South African Reserve Bank at www.resbank.co.za respectively.

Interested persons are invited to submit any substantiated comments in writing, both on a compact disc and a hard copy within three months from the date of publication of this Notice to:

The Director-General: Health

For Attention: Ms Ntobeko M. Mpanza e-mail: Ntobeko.Mpanza@health.gov.za

Director (Pharmaceutical Economic Evaluations Directorate)

Private Bag X399

PRETORIA

0001

Dr AB Xuma Building, Room C6-18A

1112 Voortrekker Rd, Pretoria Townlands 351-JR, Pretoria, 0187

Tel: (012) 395 8000 Fax: (012) 395 9165

PRETORIA

For any further enquiries please contact Ms NM Mpanza at the Directorate: Pharmaceutical Economic Evaluations: telephone: 012 395 8209/8181/4/5; e-mail: sepupdates@health.gov.za or Ntobeko.Mpanza@health.gov.za



DR MJ PHAAHLA, MP

MINISTER OF HEALTH

DATE: 23/03/2022